NASDAQ:OKYO OKYO Pharma (OKYO) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free OKYO Stock Alerts $1.47 +0.02 (+1.38%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.44▼$1.5550-Day Range$1.33▼$1.7752-Week Range$0.92▼$3.25Volume11,767 shsAverage Volume151,948 shsMarket Capitalization$42.38 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get OKYO Pharma alerts: Email Address OKYO Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside376.2% Upside$7.00 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.40) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.14 out of 5 starsMedical Sector339th out of 913 stocksBiological Products, Except Diagnostic Industry44th out of 145 stocks 3.5 Analyst's Opinion Consensus RatingOKYO Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOKYO Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.50% of the float of OKYO Pharma has been sold short.Short Interest Ratio / Days to CoverOKYO Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OKYO Pharma has recently decreased by 49.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOKYO Pharma does not currently pay a dividend.Dividend GrowthOKYO Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OKYO. Previous Next 2.8 News and Social Media Coverage News SentimentOKYO Pharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for OKYO Pharma this week, compared to 1 article on an average week.MarketBeat Follows2 people have added OKYO Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OKYO Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.97% of the stock of OKYO Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OKYO Pharma are expected to grow in the coming year, from ($0.40) to ($0.38) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About OKYO Pharma Stock (NASDAQ:OKYO)OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Read More OKYO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OKYO Stock News HeadlinesApril 9, 2024 | proactiveinvestors.comOKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader eventApril 8, 2024 | globenewswire.comOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 2, 2024 | globenewswire.comOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryMarch 31, 2024 | msn.comJapan authorities inspect second Kobayashi Pharma factory after deathsMarch 29, 2024 | msn.comJapan dietary supplement maker probes five deathsMarch 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)March 22, 2024 | msn.comOKYO Pharma gains after positive results from Phase 2 dry eye disease trialApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 22, 2024 | msn.comRelief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage StudyMarch 22, 2024 | proactiveinvestors.comOKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptomsMarch 22, 2024 | globenewswire.comOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101March 21, 2024 | proactiveinvestors.comOKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye diseaseMarch 21, 2024 | globenewswire.comOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialMarch 20, 2024 | proactiveinvestors.comOKYO Pharma to release Phase 2 dry eye disease trial results on FridayMarch 20, 2024 | globenewswire.comOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventMarch 19, 2024 | finance.yahoo.comOKYO Pharma Limited (OKYO) Stock Price, News, Quote & History - Yahoo FinanceMarch 19, 2024 | msn.comTokyo stocks open lower as gains locked in, BOJ outcome awaitedFebruary 25, 2024 | msn.comOKYO Pharma (OKYO) Price Target Increased by 20.00% to 6.12February 20, 2024 | msn.comTokyo stocks open flat as gains locked in, exporters riseFebruary 9, 2024 | proactiveinvestors.comOKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trialFebruary 9, 2024 | finance.yahoo.comOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainFebruary 2, 2024 | msn.comStock market today: Asian shares mostly rise after Wall Street rebounds led by tech stocksJanuary 31, 2024 | finance.yahoo.comOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardJanuary 18, 2024 | msn.comEagles files lawsuit in patent dispute over cancer therapyJanuary 13, 2024 | thestreet.comOKYO Pharma LimitedJanuary 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for OKYO Pharma Amid OK-101’s Promising Phase 2 Results and Increased Approval ProbabilitySee More Headlines Receive OKYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)8/20/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OKYO CUSIPN/A CIK1849296 Webwww.okyopharma.com Phone44-20-7495-2379FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+376.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-18.38Miscellaneous Outstanding Shares28,830,000Free Float17,167,000Market Cap$42.38 million OptionableNot Optionable Beta0.04 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Gary S. Jacob Ph.D. (Age 77)CEO & Executive Director Comp: $650kMr. Michael Paul Beck (Age 67)Founder Ms. Keeren Shah (Age 48)Chief Financial Officer Dr. William A. Clementi Ph.D.Pharm.D., Chief Operating OfficerDr. Rajkumar Patil Ph.D. (Age 65)Chief Scientific Officer Key CompetitorsSAB BiotherapeuticsNASDAQ:SABSNKGen BiotechNYSE:NKGNDyadic InternationalNASDAQ:DYAIEstrella ImmunopharmaNASDAQ:ESLACidara TherapeuticsNASDAQ:CDTXView All CompetitorsInsidersJohn P BrancaccioBought 16,670 shares on 9/15/2023Total: $25,005.00 ($1.50/share)View All Insider Transactions OKYO Stock Analysis - Frequently Asked Questions Should I buy or sell OKYO Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OKYO Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" OKYO shares. View OKYO analyst ratings or view top-rated stocks. What is OKYO Pharma's stock price target for 2024? 1 brokerages have issued 12-month price objectives for OKYO Pharma's shares. Their OKYO share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price. View analysts price targets for OKYO or view top-rated stocks among Wall Street analysts. How have OKYO shares performed in 2024? OKYO Pharma's stock was trading at $1.77 at the beginning of 2024. Since then, OKYO stock has decreased by 16.9% and is now trading at $1.4701. View the best growth stocks for 2024 here. Are investors shorting OKYO Pharma? OKYO Pharma saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 92,500 shares, a drop of 49.3% from the March 31st total of 182,500 shares. Based on an average trading volume of 163,700 shares, the short-interest ratio is currently 0.6 days. Currently, 0.5% of the company's shares are short sold. View OKYO Pharma's Short Interest. When is OKYO Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 20th 2024. View our OKYO earnings forecast. When did OKYO Pharma IPO? OKYO Pharma (OKYO) raised $2 million in an initial public offering on Tuesday, May 17th 2022. The company issued 625,000 shares at $4.00 per share. How do I buy shares of OKYO Pharma? Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OKYO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
